< 1 minute read
Feb. 9, 2022

Berotralstat (BCX7353): an Oral Plasma Kallikrein Inhibitor

BioCryst Kallikrein Inhibitor

oral plasma kallikrein serine protease inhibitor approved for prevention of HAE attacks from structure-based drug design berotralstat BioCryst, Birmingham, AL

drughunter.com
Drug Hunter Team

The Biocryst oral plasma kallikrein inhibitor, berotralstat (BCX7353) , was recently approved as the first non-steroidal treatment for prevention of hereditary angioedema attacks. The molecule is given orally (150 mg QD) despite having two basic amines. Interestingly for a chronically administered drug, the molecule is noted to have QT [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in